全部 标题 作者
关键词 摘要


PLACE OF 5α-REDUCTASE IN THE THERAPY FOR BENIGN PROSTATIC HYPERPLASIA

Keywords: BENIGN PROSTATIC HYPERPLASIA , 5Α-REDUCTASE INHIBITOR

Full-Text   Cite this paper   Add to My Lib

Abstract:

Twelve years ago, finasteride, the first 5α-reductase inhibitor, was introduced as drug therapy for benign prostatic hyperplasia, and more recently dutasteride has emerged as an alternative. The efficacy, safety and ability of these 5α-reductase inhibitors to reverse the natural progression of benign prostatic hyperplasia have been convincingly demonstrated and both drugs are now welt established in the medical armamentarium against the disease. Given the multifactorial etiology of benign hyperplasia, the usefulness of 5α-reductase inhibitors in combination with a adrenergic blockers has also been investigated and justified in select patients. Wider applications of 5α-reductase inhibitors are also emerging, though their perhaps most important new role as chemopreventive agents remains unclear.

Full-Text

comments powered by Disqus